Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
100% efficacy against severe Covid-19 disease and hospitalizations
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Darolutamide is developed jointly by Bayer and Orion Corporation
On track to complete the BLA submission in the first half of 2022
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘respiratory sinus arrhythmia’ (RSA)
The recommendations have been sent to the Drugs Controller General of India (DCGI) for the final approval
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Subscribe To Our Newsletter & Stay Updated
